Direct GM2A inhibitors have not been developed, but several cationic amphiphilic drugs, including desipramine and chloroquine, induce phospholipidosis and inhibit GM2 hydrolysis (55), suggesting that these drugs may be repurposed for GBM therapy. This evidence concerns the gene GM2A and glioblastoma.